Recon: Merck, Moderna vaccine cut spread of skin cancer 65% in midstage trial; FDA allows imports of unapproved Chinese chemo drugs amid shortage

• Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data (Reuters) (Endpoints)
• Analysis: Stelara patent deal puts J&J back on path to $57 bln 2025 revenue forecast (Reuters)
• US FDA delays decision on SpringWorks Therapeutics' tumor treatment (Reuters)
• FDA rejects Clovis' long-shot bid for approval of Rubraca (Fierce)
• Cancer drugmakers rise as industry meet fuels investor interest (Reuters)
• Grail says about 400 patients incorrectly informed they may have cancer (Reuters)
• FDA oncology head wants advisory panels to keep voting on new drugs (STAT)
• FDA allows temporary import of unapproved Chinese cancer drug to ease U.S. shortage (CNBC) (FT)

• AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients (Reuters) (STAT)
• Novartis drug cuts recurrence risk by 25% in early-stage breast cancer (Reuters) (STAT)
• Novo Nordisk in talks buy controlling stake in Biocorp (Reuters) (MedtechDive)
• Report finds NHS may miss out on new drugs due to rising costs (Pharmafile)
• Nigeria Forex Shortage Hurt Drug and Vaccine Supplies, Firm Says (Bloomberg)
• AstraZeneca defies geopolitics to bet on China (FT)
• Pharma Industry On How To Tackle EU Regulatory & Reimbursement Barriers To Digital Therapeutics (Pink Sheet)
• Digital Health: Commission and WHO launch landmark digital health initiative to strengthen global health security (European Commission)

• Akero says NASH drug shown to reduce liver fat by 65% in some patients (Reuters) (STAT)
• ImmunoGen drug prolongs survival of women with advanced ovarian cancer (STAT)
• Drug developer Servier's brain cancer drug slows tumor progession considerably (Reuters)
• Gilead’s CAR-T therapy prolongs survival in key blood cancer trial (STAT)
• AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing' study with many cancers: #ASCO23 (Endpoints)
• Bristol Myers' Opdivo keeps cancer at bay in more lymphoma patients than Seagen's Adcetris in PhIII: #ASCO23 (Endpoints)
• ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm (Fierce)
• Bellerophon Therapeutics trial fails despite innovative digital endpoint (STAT)
• To push antibiotic makers to be more green, a new system will certify manufacturing practices (STAT)
• ASCO: Johnson & Johnson's Balversa tops chemotherapy in bladder cancer trial (Fierce)
• J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23 (Endpoints)
• AZ notches postmarket win for bleeding reversal agent Andexxa, plans to seek full approval (Fierce)
• Biogen scraps late-stage study for Parkinson’s drug (BioPharmaDive)
• Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23 (Endpoints)
• FDA pulls paid Eisai consultant from temporary role on adcomm reviewing Eisai's new Alzheimer's drug (Endpoints)
• FDA lifts clinical hold on Foghorn’s study for blood and bone marrow cancer treatment (Endpoints)

• Exclusive: Musk's Neuralink valued at about $5 bln despite long road to market (Reuters)
• Medtronic Creates Chief Technology And Innovation Officer Role (MedtechInsight)
• FDA collects another 6,000 complaints—including 40 deaths—linked to Philips’ CPAP recall (Fierce) (MedtechDive)

• US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims (Reuters)
• Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington (STAT)